{"name":"Gruppo Italiano Trapianto di Midollo Osseo","slug":"gruppo-italiano-trapianto-di-midollo-osseo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Busulphan plus Cyclophosphamide","genericName":"Busulphan plus Cyclophosphamide","slug":"busulphan-plus-cyclophosphamide","indication":"Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies","status":"phase_3"},{"name":"Busulphan plus Fludarabine","genericName":"Busulphan plus Fludarabine","slug":"busulphan-plus-fludarabine","indication":"Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Alentuzumab","genericName":"Alentuzumab","slug":"alentuzumab","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Busulphan plus Cyclophosphamide","genericName":"Busulphan plus Cyclophosphamide","slug":"busulphan-plus-cyclophosphamide","phase":"phase_3","mechanism":"Busulphan and cyclophosphamide are alkylating agents that damage DNA in cancer cells and bone marrow cells, used together as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.","indications":["Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies","Acute myeloid leukemia","Acute lymphoblastic leukemia","Chronic myeloid leukemia"],"catalyst":""},{"name":"Alentuzumab","genericName":"Alentuzumab","slug":"alentuzumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Busulphan plus Fludarabine","genericName":"Busulphan plus Fludarabine","slug":"busulphan-plus-fludarabine","phase":"phase_3","mechanism":"Busulphan and Fludarabine together act as a myeloablative conditioning regimen that destroys bone marrow cells to prepare patients for hematopoietic stem cell transplantation.","indications":["Conditioning regimen for allogeneic hematopoietic stem cell transplantation in hematologic malignancies","Acute myeloid leukemia","Acute lymphoblastic leukemia","Chronic myeloid leukemia","Myelodysplastic syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":2,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}